NCT02267707 is a Phase 1 clinical trial of nab-paclitaxel in Pancreatic Neoplasms, sponsored by Celgene.

Who is sponsoring NCT02267707?

NCT02267707 is sponsored by Celgene.

What drugs are being tested in NCT02267707?

Interventions in NCT02267707: nab-paclitaxel, Gemcitabine.

What condition does NCT02267707 study?

NCT02267707 studies Pancreatic Neoplasms, Cholestasis.

Is NCT02267707 still recruiting?

NCT02267707 is currently terminated. Last updated 1 November 2019.

Last reviewed 2019-11-01 · How we verify

NCT02267707

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Terminated Phase 1 Last updated 1 November 2019

What this trial tests

Phase 1 trial testing nab-paclitaxel in Pancreatic Neoplasms in 1 participant. Terminated before completion.

Timeline

27 May 2015

Primary endpoint
10 February 2016

10 February 2016

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	27 May 2015
Primary completion	10 February 2016
Estimated completion	10 February 2016
Sites	6 locations across United States, Germany

Drugs / interventions tested

nab-paclitaxel (nab-paclitaxel) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →
Cholestasis — all drugs for Cholestasis →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Pancreatic Neoplasms or Cholestasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the safety and pharmacokinetic profile of nab®-paclitaxel (ABI-007) plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubinemia secondary to bile duct obstruction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Vaccaro V, Sperduti I, Vari S, Bria E, et al · · 2015 · cited 49× · PMID 25944992 · DOI 10.3748/wjg.v21.i16.4788

Verify or expand the search:

Other trials of nab-paclitaxel

Trials testing the same drug.

NCT07018063 — Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer · Phase 2 · not yet recruiting
NCT05562297 — Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
NCT06528093 — A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Ta · Phase 1 · terminated
NCT06445062 — Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06390059 — EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Li · Phase 2 · active not recruiting

Other recruiting trials for Pancreatic Neoplasms

Currently open trials in the same condition.

NCT07504471 — Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhib · Phase 2 · recruiting
NCT07139236 — Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06939023 — Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3) · NA · recruiting
NCT06953193 — Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia · NA · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02267707 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 1 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02267707.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing